🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Jamie Raskin, prominent Trump foe in U.S. House, diagnosed with cancer

Published 12/28/2022, 06:40 PM
Updated 12/28/2022, 08:51 PM
© Reuters. FILE PHOTO: U.S. Rep. Jamie Raskin announces criminal referrals against former U.S. President Donald Trump being sent to the U.S. Justice Department by the committee during the final public meeting of the U.S. House Select Committee investigating the Janu

By Gram Slattery

WASHINGTON (Reuters) -Jamie Raskin, a Democratic U.S. lawmaker who rose to prominence as he oversaw former President Donald Trump's second impeachment trial in the House of Representatives, has been diagnosed with cancer, he said on Wednesday.

"After several days of tests, I have been diagnosed with Diffuse Large B Cell Lymphoma, which is a serious but curable form of cancer," Raskin, 60, said in a statement released by his office.

"I am about to embark on a course of chemo-immunotherapy on an outpatient basis at Med Star Georgetown University Hospital and Lombardi Comprehensive Cancer Center. Prognosis for most people in my situation is excellent after four months of treatment."

Raskin, who represents part of Maryland, oversaw the House's impeachment of Trump for "incitement of insurrection," finding that he encouraged the rioters who attacked the U.S. Capitol on Jan. 6, 2021. The November 2020 election results were being certified by lawmakers when the Capitol was attacked after weeks of false claims by Trump that he had won the election.

The House voted to impeach the president, but he was acquitted in the Senate, with 57 senators voting for his conviction, short of the 67 votes required to convict.

Raskin has also served on the January 6 Committee, which investigated the Capitol attack and Trump's role in it.

In the next Congress, Raskin is set to serve as the top Democrat on the House Oversight panel. In that capacity, he will butt heads with Republicans, who are expected to launch a number of contentious investigations, including an inquiry into the business dealings of Hunter Biden, President Joe Biden's son.

© Reuters. FILE PHOTO: U.S. Rep. Jamie Raskin announces criminal referrals against former U.S. President Donald Trump being sent to the U.S. Justice Department by the committee during the final public meeting of the U.S. House Select Committee investigating the January 6 Attack on the U.S. Capitol, on Capitol Hill in Washington, U.S., December 19, 2022. REUTERS/Evelyn Hockstein

Raskin said in the statement that he expected to continue working, but that he had been advised by doctors to minimize unnecessary exposure to contagious viruses including COVID-19 during the treatment period.

Raskin told MSNBC during an interview later on Wednesday that the chemotherapy treatments were scheduled to begin this week.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.